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Abstract: The ability of oxime-containing acetylcholinesterase reactivators BT-07 (K005), BT-08 (K033), BT-07-4M
(K074), and obidoxime (H 2 LX 2 , X = Cl − , Br − ) to bind palladium(II) or platinum(II) cations was evaluated in aqueous
solutions (pH 7.4) at metal-to-ligand molar ratio varying from 1:10 to 10:1. Spectral changes were monitored within a
week after mixing the reagents in the range from 220 nm to 500 nm. Results showed that depending on chemical structure
and reaction time, oximes form two complex species of composition, [MHL] 3+ or [M 2 L] 4+ (M = Pd(II), Pt(II)). It was
also found that complexation of platinum(II) ions proceeds slower as compared to palladium(II). Conditional stability
constants of new complex species were determined spectrophotometrically using an advanced chemometric procedure,
based on the resolution of overlapping bands technique.
Key words: Bis-quaternary pyridinium aldoximes, acetylcholinesterase reactivators, palladium(II) complexes, platinum(II) complexes, UV-Vis spectroscopy

1. Introduction
Organophosphorus compounds (OPCs) are used in agriculture as insecticides (chlorpyrifos, methyl parathion,
dimethoate, azinphos-methyl, etc.) and can present serious health risks in the case of improper handling or
production and transportation accidents. 1−4 Chemical warfare nerve agents (sarin, soman, tabun, VX, etc.),
also belonging to OPCs, are classified as weapons of mass destruction according to UN Resolution 687. Both
groups are irreversible inhibitors of acetylcholinesterase, responsible for the breakdown of acetylcholine in the
synapse. 4−9 Its inhibitory eﬀect is based on phosphorylation or phosphonylation of the serine hydroxy group
at the esteric site of the active center of the enzyme and its inhibition is the life-limiting factor. 10
Currently adopted medical countermeasures against poisoning caused by OPCs consist of two approaches:
i) prophylaxis (pretreatment) with a carbamate-containing reversible inhibitor of acetylcholinesterase to protect
partially the enzyme activity, or ii) postexposure antidote treatment with combinations of an oxime-containing
cholinesterase reactivator, cholinolytic, and anticonvulsant. 11−13
The most eﬀective cholinesterase reactivators (ChRs) represent mono- or bis-quaternary pyridinium aldoximes that contain a variety of substituents in the pyridinium rings and/or diﬀerent bridges (as type/length)
∗ Correspondence:

418

ipancheva@chem.uni-sofia.bg

PANTCHEVA et al./Turk J Chem

between the rings. 14−16 The reactivation ability of oximes has been extensively studied in experimental in vivo
and in vitro assays. 17−24 The overall process of interaction of the phosphorylated enzyme and cholinesterase
reactivators is very complex and highly depends on the chemical structure of the inhibitor, type of phosphorus
residue at the enzyme active center, structure of oxime compound, and conformational and spatial interactions
between active groups of cholinesterase reactivators and phosphorus residue in the enzyme molecule. 23 Nowadays, from the wide variety of quaternary pyridinium aldoximes synthesized, only four compounds, 2-PAM,
obidoxime, HI-6, and TMB-4, are approved as drugs of the first choice in the case of nerve agent (soman, sarin,
or tabun) poisoning and are commercially available. 25−28 To the so-called “big four” of ChRs, HLö-7 should also
be added as a subject for intensive studies. 22,29 It should be strongly stressed that there are diﬃculties in ChR
application due to their fast elimination from the organism and the noncomplete recovery of enzymatic activity;
the antidotal eﬃcacy of known reactivators is also diﬀerent against various OPCs and universal antidotes are
still not developed.
On the other hand, it is well known that complexation of biologically active compounds can be applied as
an eﬃcient method to improve properties of initial compounds via various mechanisms. 30−32 From a chemical
point of view, quaternary pyridinium aldoximes are potential ligands able to bind metal ions, but only a few
studies in this field are available. It was found in 1969 that the presence of some metal ions such as Mn(II),
Mg(II), Co(II), Zn(II), and Ni(II) amplifies the reactivation ability of 2-PAM and the authors suggested possible
complex formation, although no detailed study was performed. 33 We monitored the UV-Vis spectra of 2-PAM
in the presence of a variety of divalent metal ions and were able to detect changes only in the case of Pd(II) and
Pt(II) ions, which allowed us to make some conclusions regarding these particular ions. On the other hand, the
absence of changes in 2-PAM spectra with Mn(II), Mg(II), Co(II), Zn(II), or Ni(II) ions does not mean that we
have to exclude the formation of complex species, just spectrophotometrically we were not able to obtain such
evidence and we refrain from drawing a parallel between Pd(II) coordination compounds and the other species
containing divalent metal ions mentioned above.
Later, coordination of some pyridinium aldoximes with pentacyanoferrate(II) or Pd(II) ions was monitored with respect to their determination in dosage forms and pharmaceutical formulations. 34−39
Recently we have shown that despite the limited reactivation ability of complexes in in vitro reactivation
assay of paraoxon-inhibited rat brain acetylcholinesterase 40 Pd(II) ions form two species with obidoxime
depending on reaction time. We admit that obidoxime complexes showed lower reactivation ability in this
case, but it is still unclear what will be the reality in in vivo conditions or if changing the inhibitor structure.
In the present paper we report our further studies on the capacity of bis-quaternary pyridinium aldoximes
belonging to the so-called K-oximes, after Czech researcher Kamil Kuĉa, namely BT-07 (K005 41 ) (1a), BT-08
(K033 42 ) (1b), BT-07-4M (K074 41 ) (1c), and obidoxime (1d) (Scheme), to coordinate palladium(II) (1a–1c)
or platinum(II) cations (1a–1d).

2. Results and discussion
In the present research we studied the complexation properties of particular acetylcholinesterase reactivators
(BT-07, BT-08, BT-07-4M, obidoxime), which diﬀer in the position of oxime groups (2- / 4-), as well as in the
origin and in the length of bridges between both pyridinium rings (propyl, butyl, oxy-bis-methylene). Some
of the studied compounds (obidoxime, for example) could be obtained commercially; on the other hand, there
is a protocol to prepare a variety of bis-quaternary pyridinium aldoximes according to well-known synthetic
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Obidoxime

BT-07-4M (K074)
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BT-07 (K005)
1,3-Bis(2-hydroxyiminomethylpyridinio-

BT-08 (K033)

1-yl)propane dibromide

1,4-Bis(2-hydroxyiminomethylpyridinio1-yl)butane dibromide

Scheme. Chemical structures of oxime-containing ligands.

procedures. The properties and purity of the final products are already well documented 41,42 and are not
subject of the present research.
Therapy for OPC intoxication generally faces two main problems: i) the low ability of ChRs to cross the
blood–brain barrier and ii) fast ChR metabolism, leading to formation of inactive derivatives eliminated by the
organism. Both processes result in low recovery of enzymatic activity and require regular patient treatment with
ChR. 43 One of the strategies that can be applied to improve the biological activity of drugs is their modification
by complexation in order to ensure a gradual decomposition of active species and in such a way to increase
their availability in the organism. With this main purpose we evaluated the coordination ability of the ChRs
mentioned above to bind palladium(II) or platinum(II) cations in order to find possible specific conditions for
the isolation of metal-containing complex species of definite composition.
Currently UV-Vis spectroscopy is the most suitable method for the monitoring of complexation reactions
and binding constant determination when ligands absorb in the UV-Vis area for several reasons: it works at
relatively low concentrations, which avoids complications connected to association phenomena; measurements
are possible in a variety of solvents (including water); the mathematical apparatus for complex formation is well
defined by Beer’s law; and the new chemometric approach allows to determine the binding constant without
any approximations. 44 This is the reason for selecting UV-Vis spectroscopy in the case of ChRs to study their
coordination ability towards Pt(II) or Pd(II) cations.
The UV-Vis spectra of oximes at pH 7.4 (Figure 1) indicate that ligands absorb in the range of 290–305
nm (BT-07 (1a), BT-08 (1b)) or 280–290 nm (BT-07-4M (1c), obidoxime (1d)), respectively, depending on the
positions of oxime groups (2 - or 4 -). Partial conversion of oxime to oximate takes place at pH 7.4, seen by the
less intensive absorbance band recorded in the wavelength interval from 340 to 360 nm, and this is in agreement
with data published previously. 38,45,46 In the presence of an excess of sodium carbonate, deprotonation of
420
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ligands is completed and gives rise to absorbance of oximate anions (13a–13d) in the range from 330 nm to
360 nm due to the π − π * transitions within the aromatic system. 47,48

Figure 1. UV-Vis spectra of oximes at pH 7.4 (thick lines) and in the presence of base excess (dotted lines); (H 2 L) 2+
= 4 × 10 −5 M.

Addition of increasing amount of Pd(II) ions to oxime solutions leads to gradual deprotonation of ligands,
resulting in decreased absorbance in the range of 280–300 nm and an increased one at ca. 350 nm, both
accompanied by a shoulder at ca. 420 nm. The spectra of reaction mixtures containing Pd(II) ions and BT-07
(1a), BT-08 (1b), and BT-07-4M (1c) immediately after mixing the reagents (0 h) are shown in Figure 2.
Spectral changes occurring in Pd(II)-containing reaction mixtures within a week after mixing the reagents
were further monitored. Data revealed that side reactions began to occur after 48 h, especially in the presence of
high metal excess, disturbing the equilibrium and complicating the reaction systems. Time-dependent spectra
of the Pd(II)-BT-08 system are given as an example (Figure 3).
Spectrophotometric study showed that deprotonation of oximes occurs in aqueous solutions (pH 7.4) in
the presence of palladium(II) cations and formation of complex species takes place, resulting in the appearance
of a new red-shifted absorption shoulder.
We performed analogous 1-week monitoring studies on the coordination ability of ligands 1a–1d towards
platinum(II) ions, as well. Two main points should be mentioned. First, the complexation reaction takes place
more slowly than in the case of Pd(II) cations and equilibrium is reached within 24 h after mixing the reagents.
Second, side reactions proceed faster, disrupting the equilibrium within the next 24 h (or 48 h after mixing
the reagents). Similarly to Pd(II)-containing systems, side reactions were more pronounced at higher metal(II)
excess. Time-dependent spectra of Pt(II)-BT-07-4M are shown as an illustration (Figure 4).
Summarizing, we were not able to observe the complete shift of the equilibrium towards Pd(II)/Pt(II)containing species of selected ligands 1a–1d (H 2 L 2+ ) even in the presence of very high metal(II) excess,
which makes the spectra of pure complexes unknown. Moreover, time-dependent side reactions limit the
number of spectral data that can be used in calculation processing. The pH-dependent conversion of oximes
to corresponding oximate species under the given reaction conditions should also be taken into account. All
processes mentioned above exclude the application of standard procedures for determination of the solution
421
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Figure 2. UV-Vis spectra of reaction mixtures containing Pd(II) ions and 1a–1c (0 h) at various metal-to-ligand molar
ratio, pH 7.4 (1–10, 2a–2c; 1–8, 3a–3c; 1–6, 4a–4c; 1–4, 5a–5c; 1–2, 6a–6c; 1–1, 7a–7c; 2–1, 8a–8c; 4–1, 9a–9c; 6–1,
10a–10c; 8–1, 11a–11c; 10–1, 12a–12c); (H 2 L) 2+ = 4 × 10 −5 M.

equilibrium parameters. 40 For that reason, we took the advantage of the FiNAl procedure, which is based on
resolution of overlapping bands and is a technique specially developed for quantitative analysis of such undefined,
from the viewpoint of classical spectrophotometry, systems. 49−51
Using the FiNAl protocol we calculated molar parts of the free ligands (considering their conversion to
corresponding oximates), as well as molar parts of Pd(II)/Pt(II)-containing complex species. Accounting also
for time-dependent side reactions, spectral data used for stability constant computations were limited to the
following metal-to-ligand molar ratios: Pt(II)-BT-07 – from 1:10 to 2:1, Pt(II)-BT-08 and Pt(II)-BT-07-4M –
from 1:10 to 4:1, and Pt(II)-obidoxime – from 1:10 to 10:1. The whole spectral dataset was used to evaluate
the conditional stability constants (β ’) of Pd(II)-H 2 L 2+ species.
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Figure 3. Time-dependent spectra of BT-08 (1b) in the presence of Pd(II) ions, pH 7.4, (H 2 L) 2+ = 4 × 10 −5 M: 24
h (top); 48 h (middle); 168 h (bottom).

Having the stoichiometry of a complex process, corresponding conditional stability constants were calculated using the following reaction:
n M (II) + H2 L2+

complex

Details on the mathematical apparatus of the procedure and on evaluation of stability constants can be found
in the literature. 40,49−51 Data on calculated conditional stability constants of oxime complex species at pH 7.4
are summarized (Table) and spectra of the complexes of BT-07-4M are shown (Figure 5).
Experimental results showed that oximes BT-07 and BT-08 immediately coordinate two palladium(II)
cations, forming complex species of composition [Pd 2 L] 4+ stable up to 24 h. Ligand BT-07-4M forms two
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Figure 4. Time-dependent spectra of BT-07-4M (1c) in the presence of Pt(II) ions, (H 2 L) 2+ = 4 × 10 −5 M: 0 h
(top), 24 h (middle), 48 h (bottom).
Table. Conditional stability constants ( β ’) of complex species observed (R 2 : correlation coeﬃcient).

Ligand
BT-07
BT-08
BT-07-4M
Obidoxime27

Pd(II)
Complex
[M2 L]4+
[M2 L]4+
[MHL]3+ [M2 L]4+
[MHL]3+ [M2 L]4+

lg β’
9.93
8.66
6.32 8.28
6.52 9.34

R2
0.9958
0.9947
0.9869 0.9941
0.9874 0.9927

Pt(II)
Complex
[MHL]3+
[MHL]3+
[MHL]3+
[MHL]3+

lg β’
5.91
6.61
6.28
6.26

R2
0.9643
0.9941
0.9699
0.9888

complexes of composition [PdHL] 3+ (0 h) and [Pd 2 L] 4+ (24 h), respectively, similarly to obidoxime having
both oxime groups on 4 -positions in pyridinium rings. 40 At the same time, results revealed that coordination
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Figure 5. Calculated spectra of BT-07-4M and its complexes with palladium(II) and platinum(II) cations.

of Pt(II) cations proceeds more slowly as compared to Pd(II), forming only complexes of composition [PtHL] 3+
within 24 h after mixing the reagents. We could not observe formation of species [Pt 2 L] 4+ , most likely due to
the side reactions occurring faster than in the case of Pd(II) ions.
To the best of our knowledge, very limited data exist in the literature regarding the complexation ability
of ChRs. For the first time we report equilibrium data on complex formation between quaternary oximes and
metal(II) ions. In summary, study of the coordination ability of bis-quaternary pyridinium aldoximes BT-07,
BT-07-4M, BT-08, and obidoxime revealed that interaction with Pt(II) or Pd(II) ions is a complicated process
accompanied by formation of positively charged complex species existing in equilibrium. Calculation of stability
constants under the selected conditions suggests formation of considerably stable species, but at the present
stage of the research no specific conditions for isolation of observed complexes in solid state have been found.
From the experimental data available to date it is highly speculative to propose a coordination mode of the
ligands studied. Nevertheless, we were able to observe two complex species formed by ChRs and to determine
stability constants of Pt(II) and Pd(II) complexes of ChRs. Calculations were performed using the FiNAl
protocol, because the spectra of free ligands and their complexes overlap upon complexation, and it is possible
to be done only applying advanced data processing. The experimental data obtained are a good starting point
to search for various possibilities of shifting equilibrium towards particular complex species in order to isolate
compounds of definite composition, which will enable their structural characterization and the performance of
further reactivation assays.
In conclusion, the complexation of bis-quaternary pyridinium aldoximes with Pd(II) cations at pH 7.4
leads to formation of [PdHL] 3+ or [Pd 2 L] 4+ complex species depending on the chemical structure of the
ligands and on the reaction time. It is shown that complexation of oxime-containing ChRs obidoxime, BT-07,
BT-07-4M, and BT-08 with Pt(II) cations (pH 7.4) leads to the formation of mononuclear complex species of
composition [PtHL] 3+ . The coordination reaction of platinum(II) cations is a slower process compared to that
of palladium(II) cations, but all complex species found possess considerable stability under the given reaction
conditions.
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3. Experimental
Bis-quaternary pyridinium aldoximes 1a–1d were kindly provided by the Research Laboratory of Military
Toxicology (Military Medical Academy, Sofia, Bulgaria). Diammonium tetrachloropalladate ((NH 4 )2 PdCl 4 )
and diammonium tetrachloroplatinate ((NH 4 )2 PtCl 4 ) were supplied by Sigma-Aldrich (Germany). Britton–
Robinson buﬀer (pH 7.4) was freshly prepared before experiments by mixing 8 × 10 −2 M phosphoric acid, boric
acid, and acetic acid with an appropriate volume of 4 × 10 −2 M NaOH. 52,53 All reagents were of analytical
grade; deionized water (18.2 MΩ.cm) was used in experiments.
Complexation reactions were followed spectrophotometrically (220–500 nm) on a Shimadzu UV-1800.
Stock solutions of reagents (4 × 10 −2 M) were prepared in Britton–Robinson buﬀer (pH 7.4). Appropriate
volumes of these solutions were mixed to obtain series of mixtures containing metal-to-ligand molar ratio varying
from 1:10 to 10:1 (2a–2d and 12a–12d) in a final volume of 1 mL. The spectra of oximates (13a–13d) were
recorded after addition of an excess of carbonate to solutions of 1a–1d. The final concentration of ligands
studied was kept constant at 4 × 10 −5 M. Spectra of metal-containing species were recorded against solutions
containing corresponding concentrations of palladium(II)/platinum(II) ions. Spectral changes were monitored
immediately after mixing the reagents and for up to 1 week. Calculation of molar parts of observed species and
of complexes’ spectra was performed using the FiNAl chemometric procedure. 49−51
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42. Kuca, K.; Cabal, J.; Patocka, J.; Kassa, J. Lett. Org. Chem. 2004, 1, 84-86.
43. Jokanovic, M. Curr. Top. Med. Chem. 2012, 12, 1775-1789.
44. Hirose, K. In Analytical Methods in Supramolecular Chemistry, 2nd Ed.; Schalley, C., Ed. Wiley-VCH: Weinheim,
Germany, 2012, pp. 27-66.
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